Stay updated with breaking news from Lon Dxrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Canaccord Genuity Group restated their buy rating on shares of Diaceutics (LON:DXRX – Free Report) in a research report report published on Tuesday, Marketbeat.com reports. The brokerage currently has a GBX 150 ($1.83) price objective on the stock. Separately, Canaccord Genuity Group reissued a buy rating and set a GBX 150 ($1.83) price objective on […]
Diaceutics (LON:DXRX – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity Group in a report released on Monday, Marketbeat.com reports. They presently have a GBX 150 ($1.85) price objective on the stock. Canaccord Genuity Group’s price target points to a potential upside of 64.84% from the stock’s previous close. […]
Diaceutics PLC (LON:DXRX – Get Rating) shares were down 2.4% during trading on Tuesday . The stock traded as low as GBX 81.50 ($1.01) and last traded at GBX 81.50 ($1.01). Approximately 35,194 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 57,134 shares. The stock had previously […]
Diaceutics PLC (LON:DXRX – Get Rating) shares rose 0.5% during trading on Thursday . The stock traded as high as GBX 103.80 ($1.27) and last traded at GBX 103.50 ($1.27). Approximately 28,428 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 72,339 shares. The stock had previously closed […]
1 April 2021 | 07:55am StockMarketWire.com - Healthcare diagnostic company Diaceutics said it had won a data licensing contract with a pharmaceutical company to provide COVID-19 testing data insights in the US. This contract win 'highlights that the group is in a position to address the imminent opportunity presented by the COVID-19 treatment market using its DXRX data solution capabilities,' the company said. The financial details of the contract weren't disclosed and the company said the contract value does not change management's expectations of performance for the current financial year. ...